Literature DB >> 10585285

IGF-II enhances trichostatin A-induced TGFbeta1 and p21(Waf1,Cip1, sdi1) expression in Hep3B cells.

S G Gray1, T Yakovleva, W Hartmann, M Tally, G Bakalkin, T J Ekström.   

Abstract

Cell growth and division are controlled through the actions of cyclin-dependent kinases (CDKs) and cyclin dependent kinase inhibitors (CKIs). Treatment of cell lines with Trichostatin A leads to induction of one of these CKIs, p21, and growth arrest. Induction of p21 can also occur through the actions of TGFbeta1. Latent TGFbeta1 can be activated by the M6P/IGF2R. In the present study we have examined the effect of TSA on members of the IGF axis, the CKIs p21 and p27, and also TGFbeta1 in Hep3B cells. The only member of the IGF axis to be affected by treatments was IGF2. Expression of another gene from the same chromosomal location, H19, was also affected. TGFbeta1 expression was greatly enhanced by TSA. In addition, both CKIs, p21 and p27, were upregulated by TSA. Effects of adding IGF-II or TGFbeta1 to TSA-treated cells on p21 induction were examined. The results show that the induction of p21 by TSA can be modulated by additions of IGF-II whereas addition of TGFbeta1 affects its own expression but not p21. In conclusion, the results indicate that the induction of p21 and cell growth arrest caused by Trichostatin A may involve multiple signaling pathways. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585285     DOI: 10.1006/excr.1999.4661

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells.

Authors:  Xiaohua Li; Ben D Chen
Journal:  Am J Biomed Sci       Date:  2009-06-09

2.  Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells.

Authors:  N Mishra; D R Brown; I M Olorenshaw; G M Kammer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

3.  Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

Authors:  Nilamadhab Mishra; Christopher M Reilly; Doris R Brown; Phil Ruiz; Gary S Gilkeson
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

4.  Involvement of histone hypoacetylation in Ni2+-induced bcl- 2 down-regulation and human hepatoma cell apoptosis.

Authors:  Jiuhong Kang; Dawei Zhang; Jie Chen; Changjun Lin; Qing Liu
Journal:  J Biol Inorg Chem       Date:  2004-07-03       Impact factor: 3.358

5.  Modulation of splicing events in histone deacetylase 3 by various extracellular and signal transduction pathways.

Authors:  S G Gray; A H Iglesias; B T Teh; F Dangond
Journal:  Gene Expr       Date:  2003

Review 6.  Targeting histone deacetylases for the treatment of disease.

Authors:  M W Lawless; S Norris; K J O'Byrne; S G Gray
Journal:  J Cell Mol Med       Date:  2008-11-03       Impact factor: 5.310

7.  Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation.

Authors:  Catherine A Lynch; Benjamin Tycko; Timothy H Bestor; Colum P Walsh
Journal:  Mol Cancer       Date:  2002-07-11       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.